« Compillation des Cronicques et ystores des Bretons, partie en III livretz, » par Pierre LE BAUT, secrétaire de Jean, sire de Derval.

Exemplaire enluminé, aux armes de Jean de Derval, avec plusieurs grandes miniatures, parmi lesquelles, au fol. 393 v°, une peinture à pleine page représentant Pierre Le Baut, offrant son livre à Jean de Derval et à sa femme Hélène de Laval ; au bas de cette miniature, la devise : Sans plus. — Au fol. 1 v°, on lit la devise : « Tout pour une. Argentré. Ay. »

"Attès los dits diputats no eran sinó procuradors...": relacions entre els braços i la diputació del general durant la celebració de les Corts Catalanes de 1599

La nostra comunicació s'emmarca en la Catalunya deIs inicis del regnat de Felip II (III de Castella). Té per objecte la complexa situació que es produeix quan, amb motiu d'una convocatoria de Corts, la Diputació del General es troba frec a frec amb els tres braços als quals està legalment subordinada. La convivència forçada d'ambdues institucions en el mateix quadre polític, ni que sigui durant lapses de temps relativament curts, esdevé cada cop més problematica a mesura que avança el segle XVI.

Updated survival data of the phase iii clinical trial of novottf-100a versus best standard chemotherapy for recurrent glioblastoma

NovoTTF-100A (TTF) is a portable device delivering low-intensity, intermediate-frequency, alternating electric fields using noninvasive, disposable scalp electrodes. TTF interferes with tumor cell division, and it has been approved by the US Food and Drug Administration (FDA) for the treatment of recurrent glioblastoma (rGBM) based on data from a phase III trial. This presentation describes the updated survival data 2 years after completing recruitment. Adults with rGBM (KPS ≥ 70) were randomized (stratified by surgery and center) to either continuous TTF (20-24 h/day, 7 days/week) or efficacious chemotherapy based on best physician choice (BPC). The primary endpoint was overall survival (OS), and secondary endpoints were PFS6, 1-year survival, and QOL. Patients were randomized (28 US and European centers) to either TTF alone (n ¼ 120) or BPC (n ¼ 117). Patient characteristics were balanced, median age was 54 years (range, 23-80 years), and median KPS was 80 (range, 50-100). One quarter of the patients had debulking surgery, and over half of the patients were at their second or later recurrence. OS in the intent-to-treat (ITT) population was equivalent in TTF versus BPC patients (median OS, 6.6vs. 6.0 months; n ¼ 237; p ¼ 0.26; HR ¼ 0.86). With a median follow-up of 33.6 months, long-term survival in the TTF group was higher than that in the BPC group at 2, 3, and 4 years of follow-up (9.3% vs. 6.6%; 8.4% vs. 1.4%; 8.4% vs. 0.0%, respectively). Analysis of patients who received at least one treatment course demonstrated a survival benefit for TTF patients compared to BPC patients (median OS, 7.8 vs. 6.0 months; n ¼ 93 vs. n ¼ 117; p ¼ 0.012; HR ¼ 0.69). In this group, 1-year survival was 28% vs. 20%, and PFS6 was 26.2% vs. 15.2% (p ¼ 0.034). TTF, a noninvasive, novel cancer treatment modality shows significant therapeutic efficacy with promising long-term survival results. The impact of TTF was more pronounced when comparing only patients who received the minimal treatment course. A large-scale phase III trial in newly diagnosed GBM is ongoing.